White paper for crypto-assets other than asset-referenced tokens or e-money tokens
00 Table of content
01 Date
of notification
02
Statement in accordance with Article 6(3) of Regulation (EU) 2023/1114
03
Compliance statement in accordance with Article 6(6) of Regulation (EU) 2023/1114
04
Statement in accordance with Article 6(5), points (a), (b), (c), of Regulation (EU) 2023/11144
05
Statement in accordance with Article 6(5), point (d), of Regulation (EU) 2023/1114
06
Statement in accordance with Article 6(5), points (e) and (f), of Regulation (EU) 2023/1114
07
Warning in accordance with Article 6(7), second subparagraph, of Regulation (EU) 2023/1114
This
summary should be read as an introduction to the crypto-asset white paper.
The prospective
holder should base any decision to purchase this crypto –asset on the content of the crypto-asset white
paper as a whole and not on the summary alone.
The offer to the public of this crypto-asset
does not constitute an offer or solicitation to purchase financial instruments and any such offer or
solicitation can be made only by means of a prospectus or other offer documents pursuant to the
applicable national law.
This crypto-asset white paper does not constitute a prospectus as
referred to in Regulation (EU) 2017/1129 of the European Parliament and of the Council or any other offer
document pursuant to Union or national law.
08
Characteristics of the crypto-asset
• locking-up / unlocking.
BIOX can be purchased via www.biogena.com/biox. BIOX purchasers, if qualified as consumers, have a 14 days withdrawal period. The minimum purchase amount is one (1) BIOX. The issuance price is determined in Euro with a fixed purchase price of (1) one Euro per BIOX. After locking-up BIOX in a required amount of 3,000, the BIOX holder has access to several rebates (as defined in D.7) on Biogena products and services. When locking-up BIOX a lock-up period of 12 months applies. The holder can unlock during this period, effective by the expiry of the lockup period. Upon 11 months of locking-up the BIOX holder will get a notification of his right to unlock. If the BIOX holder does not unlock during the ongoing lock-up period of 12 months a new lock-up period (of 12 months) starts automatically after expiry of the previous lockup period.
BIOX is not mandatory for using the Biogena platform, all products and services remain accessible under the standard prices. BIOX is not intended to be exchanged for goods and services or to be a currency, whatsoever. At a later date trading of BIOX on reputable trading platforms shall be possible. Rebates will be granted for 40 years, calculated beginning at the regular end of the offer phase, and subject to this Whitepaper.
Transfer of token may require payment of gas fees by the initator of the transaction.
Beyond these utilities, BIOX does not convey claims and rights against the offeror save for ownership rights over the tokens themselves and rebate rights contingent upon locking-up and the amount of token locked-up. BIOX does not grant any governance rights, whatsoever, over the offeror or any of its affiliates.
10% of BIOX sale proceeds will be donated to a welfare project of the issuer, the BIOGENA ONE WORLD FOUNDATION.
09
Further information about utility tokens
The rebates are the following and require 3,000 of locked-up BIOX:
• rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and 3,000 BIOX are being locked-up.
• participation of the BIOX holder in raffles (Verlosungen) of tickets for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and 3,000 BIOX are being locked-up.
(These rebates on products and services as well as other benefits are in the following referred to as the "rebate").
All rebates former attributable to holding and locking 30,000, 100,000 or 200,000 BIOX are no longer available, regardless of the time at which the purchase of BIOX was made. For avoidance of any doubt it is no longer possible to lock-up more than 3,000 BIOX.
Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders:
1. Personal use
BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family. The transfer, sale or commercial use of the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships with doctors/therapists, where a use within the practice is considered fair use – but not a resale outside of the practice.
2. Reasonable purchasing frequency
Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline:
• a maximum of 6 rebated orders per calendar month.
Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities.
3. Quantity limits to prevent abuse
BIOX rebates may not be used for:
• the purchase of unusually large quantities (e.g. stock purchases for resale),
• orders that objectively suggest commercial or systematic use.
4. Protection against automated or technical abuse
Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement.
5. Monitoring & transparency
The issuer is entitled to:
• randomly check the use of rebates,
• temporarily block them in case of suspected abuse,
• permanently withdraw the rebates entitlement in clear cases.
The BIOX holder will be informed transparently about all measures.
6. Fairness principle
It shall create a system that:
• offers all BIOX holders a fair advantage,
• does not create any distortion of competition,
• protects the long-term value of the BIOX ecosystem.
The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner.
10 Key
information about the offer to the public or admission to trading
Offering Phase:
• BIOX shall be offered from December 16th 2025 until June 17th 2026. The offeror is entitled to shorten or terminate the offering phase at any time. The purchase price will be 1 Euro per BIOX at all times during the offering phase.
Following the initial purchase during the offering phase:
• Following the initial purchase a waiting period of 14 days will apply. During this waiting period the BIOX holder can withdraw from the purchase of BIOX (see E.26). BIOX will be transferred to the users wallet, which is a custodial wallet;
• Following the initial purchase and the waiting period BIOX can be locked-up or unlock by the BIOX holder;
• Following the initial purchase and the waiting period BIOX can be transferred from the custodial wallet of his/her Biogena account to a wallet other than the initial custodial wallet (see D.8 milestone "Automated Transferability functionality".
• It is envisaged to list BIOX on reputable trading platforms.
A.1 Name
A.2 Legal form
A.3 Registered address
Registered address
Country
Sub-division
A.4 Head office
Head
office
Country
Sub-division
A.5
Registration date
A.6
Legal entity identifier
A.7
Another identifier required pursuant to applicable national law
A.8
Contact telephone number
A.9
E-mail address
A.10
Response time (days)
A.11
Parent company
A.12
Members of the management body
Member #1
Identity:
Business address:
Function:
Member #2
Identity:
Business address:
Function:
Member #3
Identity:
Business address:
Function:
Member #4
Identity:
Business address:
Function:
Member #5
Identity:
Business address:
Function:
Member #6
Identity:
Business address:
Function:
A.13
Business activity
Biogena Group Invest GmbH & Co KG purpose is the operation of a holding company including the acquisition, management,
and sale of participations in domestic and foreign companies of all kinds. It may finance other companies.
A.14
Parent company business activity
A.15
Newly established
A.16
Financial condition for the past three years
Number of clients:
The offeror has experienced a constant growth of clients from ca.
570,000 in 2022 to ca 600,000 in 2023 to ca. 600,000 in 2024 and to ca 900,000 in Q3/2025.
Total
assets:
The total assets of the offeror increased from EUR 77,283,079.89 thousand in 2022 to EUR
94,065,082.30 thousand in 2023 and to EUR 109,581,718.27 thousand in 2024.
Income and loss
statement:
The financial statements for the past three years have been duly prepared and submitted
on time to the Austrian commercial court register. The net profit of the offeror was EUR 5,508,880.81 in
2022, EUR 4,627,878.74 in 2023 and EUR 4,258,759.24 in 2024.
Due to increase in personnel expenses
the profits have decreased in the past three years. Further higher energy costs as well as raw materials
lead to a decrease of the net profits.
Funding sources:
The offeror's funding sources, as
reflected in its financial statements, primarily include debt investments, such as bonds, banks and
retained earnings.
A.17
Financial condition since registration
B.1
Issuer different from offerror or person seeking admission to trading
B.2
Name
N/A
B.3
Legal form
N/A
B.4 Registered address
Registered addess: N/A
Country: N/A
Sub-division: N/A
B.5 Head office
Head office: N/A
Country: N/A
Sub-division: N/A
B.6
Registration date
N/A
B.7
Legal entity identifier
N/A
B.8
Another identifier required pursuant to applicable national law
N/A
B.9
Parent company
N/A
B.10
Members of the management body
N/A
B.11
Business activity
N/A
B.12
Parent company business activity
N/A
C.1
Name
N/A
C.2
Legal Form
N/A
C.3 Registered address
Registered address: N/A
Country: N/A
Sub-division: N/A
C.4 Head office
Head office: N/A
Country: N/A
Sub-division: N/A
C.5
Registration date
N/A
C.6
Legal entity identifier
N/A
C.7
Another identifier required pursuant to applicable national law
N/A
C.8
Parent company
N/A
C.9
Reason for crypto-asset white paper preparation
N/A
C.10
Members of the management body
N/A
C.11
Operator business activity
N/A
C.12
Parent company business activity
N/A
C.13
Other persons drawing up the crypto-asset white paper according to Article 6(1), second subparagraph, of
Regulation (EU) 2023/1114
N/A
C.14
Reason for drawing the white paper by persons referred to in Article 6(1), second subparagraph, of
Regulation (EU) 2023/1114
N/A
D.1
Crypto-asset project name
D.2
Crypto-asset name
D.3
Abbreviation
D.4
Crypto-asset project description
An automated transferability
functionality shall be implemented as a milestone to be achieved in 2026. BIOX purchased by the users
will be transferred to the users custodial wallet. Automated Transferability to other wallets than the
custodial wallet will be possible upon achievement of the milestone "Automated Transferability functionality
of BIOX" (see D.8). Until achievement of this milestone, a manual transfer conducted by Tangany GmbH
of BIOX to other wallets than the custodial wallet is possible when requested by the holder.
Primary
Objective:
- encouraging the regular purchase of Biogena products and services as well as promotion
of longterm customer loyalty as well as providing funds for a welfare project of the issuer, the BIOGENA
ONE WORLD FOUNDATION.
D.5
Details of all natural or legal persons involved in implementation of crypto-asset project
Person #1
Type of person: Other person involved in implementation
Name of person:
Business address of person:
Domicile of company: Germany
Person #2
Type of person: Development team
Name of person:
Business address of person:
Domicile of company: Germany
Person #3
Type of person: Other person involved in implementation
Name of person:
Business address of person:
Domicile of company: Germany
Person #4
Type of person: Development team
Name of person:
Business address of person:
Domicile of company: Austria
Person #5
Type of person: Crypto-asset service provider
Name of person:
Business address of person:
Domicile of company: Germany
D.6
Utility token classification
D.7 Key
features of goods or services for utility token projects
• rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up.
• participation of the BIOX holder in raffles (Verlosungen) for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up.
(These rebates on products and services as well as other benefits are in the following referred to as the "rebate").
By locking-up BIOX a lock-up period of 12 months will apply. During that time, transfer of BIOX as well as unlocking BIOX shall not be possible. There are no other restrictions on transferability of BIOX. Each transfer requires gas fees. The automated transfer of BIOX to other wallets of a BIOX holder is possible upon its implementation (D.8), until achieving this milestone a manual transfer is possible and provides by Tangany GmbH. The transfer has to be requested by the holder. To lock or unlock BIOX, the token must be deposited in the custodial wallet of the user provided by Tangany GmbH. This wallet must be accessed via the BIOX holders account www.biogena.com/biox. Locking-up on any other wallet is not possible. Locking-up does not mean that the tokens are transferred to another party, a wallet or a contract. The token shall remain in the economic sphere of the holder on the custodial wallet of the user, but shall be locked-up for the certain period of time. At the time of drafting this whitepaper 3.0 (20th of March 2026) there is no possibility of trading BIOX on trading platforms. It is envisaged that further possibilities of trading BIOX on reputable trading platforms shall be made available on www.biogena.com/biox.
D.8 Plans for the token
Description of past milestones
Description of future milestones
Automated Transferability functionality (Ongoing,
estimated 2026):
• As of the publication date (F.10) the automated transferability functionality of BIOX is not yet available. The offeror envisages to accomplish this functionality as soon as
possible. In the meantime, BIOX can be transferred manually by Tangany GmbH to any other wallet by individual request of the individual holder.
Admission to trading and expansion of exchange Listings (Ongoing 2026):
Following the end of the (regular or shortened) offering phase BIOX is envisaged to be admitted to trading on one or several selected centralised exchanges. This
admission process is at the discretion of the offeror and involves meeting their respective listing requirements. The costs involved for the listing of BIOX on a trading
platform or exchange will be borne by the offeror. For the avoidance of any doubt, the investor shall bear its own costs involved with the trading on a platform or exchange.
• Listing on further major centralised exchanges to enhance liquidity and global access.
D.9
Resource allocation
D.10
Planned use of collected funds or other tokens
as well as for charitable and research-related purposes, as set forth below as part of the business areas (Geschäftszweige) of the offeror and its group companies.
The planned use of funds is broken down as follows (calculated based on 35,000,000 BIOX being sold):
• 30% will be invested in the further development of the customer-centric IT and communications infrastructure of the Biogena ecosystem. The aim is to improve the digital customer experience, in particular by optimising personalisation, service quality, data integration, security and user- friendliness within the Biogena customer portal, the Biogena app and the online and store systems;
• 30% will be invested in the construction of the first 'Welcome to Yourself Resorts'. These locations will serve as practical implementations of the Biogena wellbeing concept, health prevention and the combination of relaxation, diagnostics and lifestyle. The resorts will be established as model locations for the Biogena health ecosystem;
• 30% are dedicated to product development, research and diagnostics. The focus is on scientifically based innovation projects in the areas of osteoporosis, silent inflammation, stress management and diabetes prevention, as well as on the expansion of tele-medical consulting services and diagnostic systems (e.g. Biogena Wellbeing Check). The aim is to continuously improve the scientific basis and applicability of Biogena health solutions;
• 10% of the net proceeds will be donated to the BIOGENA ONE WORLD FOUNDATION – Stiftung für Gesundheit, Klimaschutz & Umweltschutz sowie Fairness & Gerechtigkeit a charitable foundation currently being established by the offeror). The funds will be used to support initiatives aimed at protecting nature and the environment, particularly through CO2 sequestration, the promotion of biodiversity and marine conservation, as well as childrens rights and equal opportunities by supporting education, nutrition, sports and exercise programmes, the provision of clean drinking water supplies, and more. Further, projects which are CO2 relevant and supported by the BIOGENA ONE WORLD FOUNDATION should be included in the so called Biogena Climate Positive Plus-Strategy, a self-commitment of the issuer to reduce CO2.
E.1
Public offering or admission to trading
E.2
Reasons for public offer or admission to trading
E.3 Fundraising target
Target
expressed in currency:
Target
expressed in units:
Target
expressed in digital token identifier:
E.4 Minimum subscription goals
Goals
expressed in currency:
Goals
expressed in units:
Goals
expressed in digital token identifier:
E.5 Maximum subscription goals
Goals
expressed in currency:
Goals
expressed in units:
Goals
expressed in digital token identifier:
E.6
Oversubscription acceptance
E.7
Oversubscription allocation
Issue price details
E.8
Issue price
E.9
Official currency determining issue price
E.9 Any
other tokens determining issue price
E.10 Subscription fee
Fee
expressed in currency:
Fee
expressed in units:
Fee
expressed in digital token identifier:
E.11
Offer price determination method
E.12
Total number of offered or traded other tokens
E.13
Targeted holders
E.14
Holder restrictions
effective by the expiry of the lockup period. Upon 11 months of locking-up the BIOX holder will get a notification of his right to unlock. If the BIOX holder does not unlock
during the ongoing lockup period (of 12 months) a new lockup period (of 12 months) starts automatically after expiry of the previous lockup period.
In case the holder holds more BIOX than the amount locked-up (3,000), the remaining amount of BIOX is not locked-up, but remains in the holder's wallet.
The remaining amount of BIOX is transferable by individual request of the BIOX holder. After receival of the request, Tangany GmbH conducts the manual transfer of BIOX
to other wallets then the custodial wallet.After the achievement of the milestone "automated transferability functionality" (D.8) the remaining amount
of BIOX will be transferable for the holder.
Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders:
1. Personal use
BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family.
The transfer, sale or commercial use of the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships
with doctors/therapists, where a use within the practice is considered fair use – but not a resale outside of the practice.
2. Reasonable purchasing frequency
Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline:
• a maximum of 6 rebated orders per calendar month.
Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities.
3. Quantity limits to prevent abuse
BIOX rebates may not be used for:
• the purchase of unusually large quantities (e.g. stock purchases for resale),
• orders that objectively suggest commercial or systematic use.
4. Protection against automated or technical abuse
Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement.
5. Monitoring & transparency
The issuer is entitled to:
• randomly check the use of rebates,
• temporarily block them in case of suspected abuse,
• permanently withdraw the rebates entitlement in clear cases.
The BIOX holder will be informed transparently about all measures.
6. Fairness principle
It shall create a system that:
• offers all BIOX holders a fair advantage,
• does not create any distortion of competition,
• protects the long-term value of the BIOX ecosystem.
The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner.
Locking-up or unlocking can only be initiated via www.biogena.com/biox. The aggregate amount of token locked-up has to be 3,000 BIOX, a different amount of BIOX cannot be locked-up.
The amount of BIOX held by the holder is subject to their discretion, and can exceed the amount of 3,000 locked-up BIOX.
Besides the restriction during locking-up periods, no holder restrictions shall apply beyond legal prohibitions. Therefore, the sale is prohibited to potential purchasers
who are prohibited from participation due to applicable regulations and legal requirements.
Each transfer requires payment of gas fees. The gas fees for the initial transfer of BIOX will be borne by the issuer. A gas fee for a transfer from the custodial wallet
to a third party wallet will be borne by the issuer until 16.12.2028. Other fees and costs for locking-up or unlocking as well as trading of BIOX on centralised exchanges,
if admission is granted following the initial transfer as well as initial locking-up shall be borne by the holder.
E.15
Reimbursement notice
E.16
Refund mechanism
Following the initial purchase of BIOX a waiting period of 14 days applies. During this waiting period locking-up of BIOX is not possible.
BIOX holder may send the refund request by e-mail (A.9) or in writing to the business address (A.3). If the request is submitted on time,
a refund will be granted according to the refund mechanism in E.26.
E.17
Refund timeline
E.18
Offer phases
to shorten or terminate the offering phase at any time. The total number of BIOX is not limited by number.
E.19
Early purchase discount
E.20
Time-limited offer
E.21
Subscription period beginning
E.22
Subscription period end
E.23
Safeguarding arrangements for offered funds or other tokens
E.24
Payment methods for other token purchase
credit card payments. Payment methods are subject to change.
E.25
Value transfer methods for reimbursement
The initially amount will be transferred to the same bank account that the initial sum was transferred from. Art 13 MiCAR applies.
E.26
Right of withdrawal
directly from a provider are entitled to a right of withdrawal. Retail investors have a period of 14 calendar days to withdraw their consent to the purchase of crypto-assets other than
asset-referenced tokens and electronic money tokens free of charge and without providing any reason. The withdrawal period begins on the day the retail investor gives consent
to the purchase of these crypto-assets.
E.27
Transfer of purchased other tokens
can access via his/her account at www.biogena.com/biox. Upon locking-up of BIOX the respective amount of token in the holders custodial wallet is locked by a technical mechanism
for the duration of the lock-up period. BIOX can be transferred upon expiry of the withdrawal period as well as upon request of the BIOX holder manually by Tangany GmbH and upon implementation of the automated transferability functionality by the holder (see D.8).
.
E.28
Transfer time schedule
E.29
Purchaser's technical requirements
a separate Ethereum wallet may be required to transfer gas fees.
In case the BIOX holder whishes to trade BIOX publicly an additional account at a reputable trading platform will be require to trade BIOX.
Other token services provider characteristics
E.30
Other token service provider (CASP) name
E.31
CASP identifier
E.32
Placement form
Trading platforms characteristics
E.33
Trading platforms name
It is envisaged to implement this in the future.
E.34
Trading platforms market identifier code (MIC)
E.35
Trading platforms access
E.36
Involved costs
E.37
Offer expenses
E.38
Conflicts of interest
he has financial and economic interests that may differ from those of the issuer and thus may represent a potential conflict of interest.
All managing directors of the issuer's general partner also hold management positions in other companies of the Biogena Group, which may also lead to a potential conflict of interest.
In the opinion of the offeror, there are no active conflicts of interest.
E.39
Applicable law
E.40
Competent court
F.1
Crypto-asset type
F.2
Other token functionality
F.3
Planned application of functionalities
It is the users discretion to lock-up BIOX as activation of rebates requires locking-up of BIOX by the BIOX holder (see 09, D.7, E.14). The
locking-up period is at least 12 months, to make use of the granted rebates and other benefits. The holder is entitled to the benefits (D.7) immediately after locking-up the
required amount of BIOX.
A description of the characteristics of the other token, including the data necessary for classification of
the crypto-asset white paper in the register referred to in Article 109 of Regulation (EU) 2023/1114, as
specified in accordance with paragraph 8 of that Articles
F.4
Type of crypto-asset white paper
F.5
Type of submission
F.6
Other token characteristics
F.7
Commercial name or trading name
F.8
Website of the issuer
F.9
Starting date of offer to the public or admission to trading
F.10
Publication date
F.11
Any other services provided by the issuer
F.12
Language or languages of white paper
F.13
Digital token identifier code used to uniquely identify the crypto-asset or each of the several crypto assets
to which the white paper relates, where available
F.14
Functionally fungible group digital token identifier, where available
F.15
Voluntary data flag
F.16
Personal data flag
F.17
LEI eligibility
F.18
Home member state
F.19
Host member states #1
G.1
Purchaser rights and obligations
offeror, any affiliates, or any other third parties, beyond the token's functionalities as described in this white paper, namely, locking-up.
Beyond these utilities, BIOX does not convey any claims or rights, other than ownership rights over the tokens themselves and rebates as set forth in this white paper.
BIOX does not grant rights to dividends, interest payments, principal repayments, or corporate voting. Holding BIOX does not create any debt or equity relationship between the holder and the offeror (or its affiliates).
G.2
Exercise of rights and obligations
and not a higher or lower amount of BIOX. However, the amount of BIOX purchased and held by the holder remains at the holder's discretion. BIOX holders can lock-up
their tokens via their account at www.biogena.com/biox, which offers a frontend interface for locking-up. The corresponding backend for the locking-up procedure is provided by the offeror. By locking-up BIOX the rebate will be automatically deducted of the BIOX holders purchase or booking. It is the BIOX holders choice whether BIOX shall be locked-up or unlocked. Following the initial purchase, BIOX is not locked-up automatically.
G.3
Conditions for modifications of rights and obligations
New legislation applicable to the
Biogena Experience Token Project, can lead to changes due to compliance with mandatory laws.
G.4
Future public offers
G.5
Issuer retained other token
G.6
Utility token classification
G.7 Key
features of goods or services utility tokens
rebates on the following, grant benefits and require 3,000 locked-up BIOX:
• rebates of 30% of the purchase price (regular price and promotional or discounted price) on all Biogena products, biohacking applications and wellbeing checks and
subscriptions for every single purchase for a maximum period of 40 years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX
are being held and thereof 3,000 BIOX are being locked-up.
• participation of the BIOX holder in raffles (Verlosungen) of tickets for at least 300 different cultural and sporting events. The raffles shall take place once a year and shall
contain each of about 100 tickets for the "Jedermann"-Festival, Kitzbühel Streif ski event and Skybox VIP invitations for the Red Bull Arena in Salzburg. Further events shall
be made available, such as specific Health Days and a yearly dinner with the Founder and Management Team. The raffles shall be conducted for a maximum period of 40
years, calculated beginning at the regular end of the offer phase, if and as long as at least 3,000 BIOX are being held and thereof 3,000 BIOX are being locked-up.
Further, to ensure responsible and sustainable use of BIOX and its granted rebates, the following fair use principle applies to all BIOX holders:
1. Personal use
BIOX rebates are intended exclusively for the personal use of the BIOX holder and for personal use within the immediate family. The transfer, sale or commercial use of
the rebates is not permitted. An exception to this shall apply within the framework of existing business partner relationships with doctors/therapists, where a use within the
practice is considered fair use – but not a resale outside of the practice.
2. Reasonable purchasing frequency
Rebates may be used within the scope of a normal and reasonable purchasing frequency. The following applies as a guideline:
• a maximum of 6 rebated orders per calendar month.
Higher frequencies are possible, but must be in a reasonable proportion to personal consumption and must not reflect resale activities.
3. Quantity limits to prevent abuse
BIOX rebates may not be used for:
• the purchase of unusually large quantities (e.g. stock purchases for resale),
• orders that objectively suggest commercial or systematic use.
4. Protection against automated or technical abuse
Any form of automated ordering, price manipulation or circumvention of the rules of use will result in the suspension or termination of the rebate entitlement.
5. Monitoring & transparency
The issuer is entitled to:
• randomly check the use of rebates,
• temporarily block them in case of suspected abuse,
• permanently withdraw the rebates entitlement in clear cases.
The BIOX holder will be informed transparently about all measures.
6. Fairness principle
It shall create a system that:
• offers all BIOX holders a fair advantage,
• does not create any distortion of competition,
• protects the long-term value of the BIOX ecosystem.
The issuer undertakes to apply this principle in a customer-friendly, proportionate and transparent manner.
G.8 Utility tokens redemption
G.9 Non-trading request
G.10 Other tokens purchase or sale modalities
G.11 Other tokens transfer restrictions
G.12 Supply adjustment protocols
G.13 Supply adjustment mechanisms
Other token schemes details
G.14 Token value protection schemes
G.15 Token value protection schemes description
G.16 Compensation schemes
G.17 Compensation schemes description
G.18 Applicable law
G.19 Competent court
H.1 Distributed ledger technology (DTL)
H.2 Protocols and technical standards
H.3 Technology used
H.4 Consensus mechanism
H.5 Incentive mechanisms and applicable fees
H.6 Use of distributed ledger technology
H.7 DLT functionality description
Other token audit details
H.8 Audit
H.9 Audit outcome
I.1 Offer-related risks
Access to BIOX requires an account at www.biogena.com/biox. As BIOX holder holds the token with crypto-asset services providers offering custody services, the BIOX holder could face the risk of such service providers failing to properly execute their instructions with regard to the storage methods, such as hot trading, hot storage, cold storage, and deep cold storage. In addition, BIOX held with a custodian may not be separable in favor of the investor in the event of insolvency of the custodian or a third-party financial intermediary. Finally, the custodians can face risk of cyberattacks. As a result, of all such custody-related events, the investors will face the risk of loss.
• Technological risk:
The migration of BIOX to other crypto currencies may be subject to technical malfunctions or errors. In the worst-case scenario, these issues could lead to the loss of tokens.
I.2 Issuer-related risks
Holding BIOX does not entitle the holder to any claim, collateral, or segregation of assets from the offeror. In a hypothetical insolvency, BIOX holders would not have special priority rights.
• Business Risk:
The offeror's success in micronutrient and longevity markets can indirectly influence the perceived value of BIOX. Downturns, regulatory issues, or decreased user trust could negatively impact any BIOX’s secondary market price.
• Credit and Counterparty Risk:
The offeror relies on various counterparties; high-profile defaults or failures can impact the platform’s operations and user confidence, indirectly affecting BIOX demand.
• Operational Risk:
Technical or process failures could undermine trust in the ecosystem, potentially reducing demand or utility for BIOX.
• Third-Party Risk:
Many back-office or liquidity-related services rely on external providers. Failures or vulnerabilities at these providers can negatively affect BIOX availability, liquidity, or usage.
• Regulatory Risk:
The evolving regulatory landscape may impose new constraints on the offeror, which could indirectly affect the value or usability of BIOX.
I.3 Other tokens-related risks
Upon implementation of trading BIOX on trading plattforms, BIOX's price can be volatile, and investors could incur substantial losses, including a complete loss of value.
• High Volatility & Illiquidity:
BIOX is not backed by physical assets or guaranteed returns. Secondary market liquidity can be unpredictable; low liquidity can deteriorate price swings.
• Abrupt Market Events:
Political, economic, or market-specific incidents (e.g. exchange hacks, macroeconomic shifts) can quickly affect BIOX prices.
• Market Abuse Risks:
Even under Regulation (EU) 2023/1114, certain manipulative tactics or fraudulent practices can persist in crypto-asset markets, posing volatility and transparency challenges.
• Regulatory Risk:
Different jurisdictions have different rules on crypto-assets. Changes in law or enforcement actions could disrupt BIOX trading or usage in certain regions.
• ESG-Related Risk:
Ethereum's (and corresponding EVM-based chains) move to proof-of-stake has reduced energy consumption, but some investors may still view crypto negatively from an ESG standpoint.
• Taxation Risk:
BIOX transactions may be taxed differently across Member States or non-EU jurisdictions. Regulatory or classification changes can alter tax obligations, potentially impacting investment returns. It is the BIOX holders sole responsibility to be aware of taxation and fiscal treatment of BIOX in accordance with the acquisition and possible trading of BIOX.
I.4 Project implementation-related risks
As the issuer is seeking trading admission, risk of delay in the admission processor time line may as well as technical implementation risks may occur.
• Risks associated with project implementation:
Risks of delay in or failure of the achievement of the milestones (D.8) may apply. Projects implementation risks are not limited to the previously mentioned risks.
I.5 Technology-related risks
As a ERC-20 token, BIOX depends on Ethereum's and other compatible blockchain's reliability. Network disruptions, consensus failures, or severe bugs could impair transfers or usage.
• Cyber Risks:
Attacks targeting private keys, smart contract exploits, or node manipulations could lead to losses or a collapse of user confidence.
• Smart Contract Risks:
Coding errors or unforeseen vulnerabilities in BIOX's migration/governance contracts could lead to partial or total token loss for certain users.
• Consensus Mechanism Attacks:
While proof-of-stake is designed to be secure, a 51% attack is theoretically possible if an entity controls a majority stake, potentially invalidating honest transactions.
• Irreversibility of Transactions:
Once BIOX is transferred on-chain, the transaction is final. Mistakes (e.g. sending to a wrong address) typically cannot be reversed.
• Forking Risk:
Ethereum or other relevant chains can fork, creating parallel tokens or splitting the chain. This may result in confusion, lost liquidity, or partial devaluation of existing BIOX.
• Limited Control:
The issuer cannot control global internet routing, user hardware, or external factors that might impair connectivity to the BIOX ecosystem.
• Unanticipated Risks:
New and evolving technology can reveal unanticipated security issues or usage patterns, leading to additional unforeseen risks.
I.6 Mitigation measures
The offeror applies rigorous standards for selecting third-party service providers and designs robust internal procedures to safeguard operations.
• Liquidity & Volatility Management:
The offeror may engage in liquidity measures, buybacks, or promotional campaigns to encourage adoption and manage volatility. The offeror or its subsidiary companies may make use of the amount of BIOX held in respect of any measures as mentioned in the foregoing sentence.
• Security Practices:
Continual monitoring of potential threats, internal bug bounty programmes, and, where feasible, external audits help mitigate some technology-related risks.
J.1 Adverse impacts on climate and other environment-related adverse impacts
Mandatory information on principal adverse impacts on the climate and other environment-related adverse
impacts of the consensus mechanism
General information about adverse impacts
S.1 Name
S.2 Relevant legal entity identifier
S.3 Name of the crypto-asset
S.4 Consensus mechanism
S.5 Incentive mechanisms and applicable fees
S.6 Beginning of period to which disclosed information relates
S.7 End of period to which disclosed information relates
Mandatory key indicator
S.8 Energy consumption
Sources and methodologies
S.9 Energy consumption sources and methodologies
According to the CCRI a transaction requires on average for a transaction volume of 1,6 Million Transactions per day an energy consumption of 0,0045 kWh per Token.
BIOX expects a yearly transaction volume of maximum 50.000 On-Chain Transactions on the Ethereum-Layer-1. Therefore, an energy consumption of 225,00 kWh/p.a (per year) is expected.
Sources used for data of this calculation are carbon-ratings.com and ethereum.org.
Supplementary information on principal adverse impacts on climate and other environment-related adverse
impacts of consensus mechanism
Supplementary key indicators
S.10 Renewable energy consumption Not applicable as total amount of energy used for the validation of
transactions and the maintenance of the integrity of the distributed ledger
of transactions, expressed per calendar year does not exceed 500,000 kwh.
S.11 Energy intensity
n/a see S.8
S.12 Scope 1 DLT GHG emissions - controlled
n/a see S.8
S.13 Scope 2 DLT GHG emissions - purchased
n/a see S.8
S.14 GHG intensity
n/a see S.8
Sources and methodologies
n/a see S.8
S.15 Key energy sources and methodologies
S.16 Key GHG sources and methodologies
Optional information on principal adverse impacts on the climate and on other environment-related adverse
impacts of the consensus mechanism
Optional indicators
S. 17 Energy mix
n/a see S.8
S.18 Energy use reduction
Energy use reduction target (absolute value):n/a see S.8
Energy use reduction target (percentage):n/a see S.8
S.19 Carbon intensity (kgCO2e/kWh)
n/a see S.8
S.19 Carbon intensity (kgCO2e/kWh)
n/a see S.8
S.20 Scope 3 DLT GHG emissions - value chain
n/a see S.8
S.21 GHG emissions reduction targets or commitments
n/a see S.8
S.22 Generation of waste electrical and electronic equipment (WEEE)
n/a see S.8
S.23 Non-recycled WEEE ratio
n/a see S.8
S.24 Generation of hazardous waste
n/a see S.8
S.25 Generation of waste (all types)
n/a see S.8
S.26 Non-recycled waste ratio (all types)
n/a see S.8
S.27 Waste intensity (all types)
n/a see S.8
S.28 Waste reduction targets or commitments (all types)
n/a see S.8
S.29 Impact of use of equipment on natural resources
n/a see S.8
S.30 Natural resources use reduction targets or commitments
n/a see S.8
S.31 Water use
n/a see S.8
S.32 Non recycled water ratio
n/a see S.8
Sources and methodologies
n/a see S.8
S.33 Other energy sources and methodologies
n/a see S.8
S.34 Other GHG sources and methodologiesn/a see S.8
S.35 Waste sources and methodologies
n/a see S.8
S.36 Natural resources sources and methodologies
n/a see S.8